Equities research analysts predict that Phio Pharmaceuticals Corp (NASDAQ:PHIO) will report ($0.56) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Phio Pharmaceuticals’ earnings. Phio Pharmaceuticals posted earnings per share of ($4.40) during the same quarter last year, which indicates a positive year over year growth rate of 87.3%. The business is expected to issue its next earnings results on Tuesday, November 10th.
On average, analysts expect that Phio Pharmaceuticals will report full year earnings of ($2.24) per share for the current financial year, with EPS estimates ranging from ($2.35) to ($2.12). For the next financial year, analysts anticipate that the company will post earnings of $0.29 per share, with EPS estimates ranging from ($2.10) to $2.68. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that cover Phio Pharmaceuticals.
Phio Pharmaceuticals (NASDAQ:PHIO) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.31.
Hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. bought a new position in Phio Pharmaceuticals in the first quarter worth about $38,000. Wedbush Securities Inc. bought a new position in Phio Pharmaceuticals in the second quarter worth about $73,000. Finally, Sabby Management LLC bought a new position in shares of Phio Pharmaceuticals during the first quarter valued at approximately $452,000. 2.26% of the stock is owned by institutional investors.
Shares of NASDAQ:PHIO traded up $0.05 during midday trading on Friday, hitting $2.19. 116,309 shares of the stock traded hands, compared to its average volume of 701,484. The stock has a market capitalization of $12.66 million, a PE ratio of -0.20 and a beta of 2.36. The business’s 50 day moving average is $2.29 and its two-hundred day moving average is $2.28. The company has a quick ratio of 10.33, a current ratio of 10.33 and a debt-to-equity ratio of 0.03. Phio Pharmaceuticals has a one year low of $1.60 and a one year high of $18.15.
Phio Pharmaceuticals Company Profile
Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye.
Featured Story: The Discount Rate – What You Need to Know
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.